Pepcid AC ANDA?
This article was originally published in The Tan Sheet
Executive Summary
An FDA response letter dated July 6 deems that famotidine 10 mg (J&J/Merck's Pepcid AC) in an orally dissolving strip formulation is suitable for ANDA submission. Approval of the application would mark the first time the strip technology would be used to deliver a drug, though many breath fresheners including Pfizer's Listerine PocketPaks already are available in the formulation. The petition, filed by Lachman Consultant Services on behalf of an unnamed firm, was submitted in August 2004 (1"The Tan Sheet" Aug. 16, 2004, p.10)...
You may also be interested in...
Orally Dissolving Strips To Melt Away Heartburn? ANDA Suitability Sought
An orally disintegrating strip form of Johnson & Johnson/Merck's Pepcid AC (famotidine 10 mg) could be heading towards the market if FDA looks favorably upon a pending ANDA suitability petition
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.